Male Breast Cancer Screening

Variant: 1 Adult male. Breast cancer screening. Higher-than-average risk.

Procedure	Appropriateness Category	Relative Radiation Level
Digital breast tomosynthesis screening	Usually Appropriate	☢☢
Mammography screening	Usually Appropriate	☢☢
US breast	Usually Not Appropriate	O
Mammography with IV contrast	Usually Not Appropriate	☢☢
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without and with IV contrast abbreviated	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast abbreviated	Usually Not Appropriate	O
Sestamibi MBI	Usually Not Appropriate	☢☢☢

Variant: 2 Adult male. Breast cancer screening. Average risk.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Not Appropriate	O
Digital breast tomosynthesis screening	Usually Not Appropriate	☢☢
Mammography screening	Usually Not Appropriate	☢☢
Mammography with IV contrast	Usually Not Appropriate	☢☢
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without and with IV contrast abbreviated	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast abbreviated	Usually Not Appropriate	O
Sestamibi MBI	Usually Not Appropriate	☢☢☢

Variant: 3 Adult male, younger than 25 years of age. Breast cancer screening. Any risk.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Not Appropriate	O
Digital breast tomosynthesis screening	Usually Not Appropriate	☢☢
Mammography screening	Usually Not Appropriate	☢☢
Mammography with IV contrast	Usually Not Appropriate	☢☢
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without and with IV contrast abbreviated	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast abbreviated	Usually Not Appropriate	O
Sestamibi MBI	Usually Not Appropriate	☢☢☢

Panel Members

Phoebe E. Freer, MD^a; Colleen H. Neal, MD^b; Ann Brown, MD^c; Debbie L. Bennett, MD^d; Michael R.. Cassidy, MD^e; Alison Chetlen, DO^f; Elizabeth H. Dibble, MD^g; Sharon H. Giordano, MD, MPH^h; Heather I. Greenwood, MDⁱ; Janet Hurley, MD^j; Lillian K. Ivansco, MD, MPH^k; Sharp F. Malak, MD, MPH^l; Gaiane M. Rauch, MD, PhD^m; Beatriu Reig, MD, MPHⁿ; Puneet Singh, MD^o; William Small Jr., MD^p; Eren D. Yeh, MD^q; Priscilla J. Slanetz, MD, MPH^r.

Summary of Literature Review

Introduction/Background

Discussion of Procedures by Variant

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
A. Digital breast tomosynthesis screening

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
B. Mammography screening

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
C. Mammography with IV contrast

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
D. MRI breast without and with IV contrast

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
E. MRI breast without and with IV contrast abbreviated

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
F. MRI breast without IV contrast

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
G. MRI breast without IV contrast abbreviated

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
H. Sestamibi MBI

Variant 1: Adult male. Breast cancer screening. Higher-than-average risk.
I. US breast

Variant 2: Adult male. Breast cancer screening. Average risk.

Variant 2: Adult male. Breast cancer screening. Average risk.
A. Digital breast tomosynthesis screening

Variant 2: Adult male. Breast cancer screening. Average risk.
B. Mammography screening

Variant 2: Adult male. Breast cancer screening. Average risk.
C. Mammography with IV contrast

Variant 2: Adult male. Breast cancer screening. Average risk.
D. MRI breast without and with IV contrast

Variant 2: Adult male. Breast cancer screening. Average risk.
E. MRI breast without and with IV contrast abbreviated

Variant 2: Adult male. Breast cancer screening. Average risk.
F. MRI breast without IV contrast

Variant 2: Adult male. Breast cancer screening. Average risk.
G. MRI breast without IV contrast abbreviated

Variant 2: Adult male. Breast cancer screening. Average risk.
H. Sestamibi MBI

Variant 2: Adult male. Breast cancer screening. Average risk.
I. US breast

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
A. Digital breast tomosynthesis screening

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
B. Mammography screening

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
C. Mammography with IV contrast

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
D. MRI breast without and with IV contrast

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
E. MRI breast without and with IV contrast abbreviated

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
F. MRI breast without IV contrast

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
G. MRI breast without IV contrast abbreviated

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
H. Sestamibi MBI

Variant 3: Adult male, younger than 25 years of age. Breast cancer screening. Any risk.
I. US breast

Summary of Highlights

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Gender Equality and Inclusivity Clause

The ACR acknowledges the limitations in applying inclusive language when citing research studies that predates the use of the current understanding of language inclusive of diversity in sex, intersex, gender, and gender-diverse people. The data variables regarding sex and gender used in the cited literature will not be changed. However, this guideline will use the terminology and definitions as proposed by the National Institutes of Health.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

References

1.	Sulieman A, Salah H, Rabbaa M, et al. Assessment of male patients' average glandular dose during mammography procedure. Applied Radiation & Isotopes. 193:110626, 2023 Mar.
2.	Elimimian EB, Elson L, Li H, et al. Male Breast Cancer: A Comparative Analysis from the National Cancer Database. World J Mens Health 2021;39:506-15.
3.	Hassett MJ, Somerfield MR, Baker ER, et al. Management of Male Breast Cancer: ASCO Guideline. Journal of Clinical Oncology. 38(16):1849-1863, 2020 06 01.
4.	American Cancer Society. Key Statistics for Breast Cancer in Men. Available at: https://www.cancer.org/cancer/types/breast-cancer-in-men/about/key-statistics.html.
5.	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12-49.
6.	Niell BL, Lourenco AP, Moy L, et al. ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast. J Am Coll Radiol 2018;15:S313-S20.
7.	Leone J, Hassett MJ, Freedman RA, et al. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol 2024;10:508-15.
8.	Woods RW, Salkowski LR, Elezaby M, Burnside ES, Strigel RM, Fowler AM. Image-based screening for men at high risk for breast cancer: Benefits and drawbacks. [Review]. Clinical Imaging. 60(1):84-89, 2020 Mar.
9.	Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 2018;29:405-17.
10.	Doebar SC, Slaets L, Cardoso F, et al. Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Mod Pathol. 30(4):509-518, 2017 Apr.
11.	Medscape. Breast Cancer in Men Overview of Male Breast Cancer. Diagnosis. Available at: https://emedicine.medscape.com/article/1954174-overview#a3.
12.	Gao Y, Goldberg JE, Young TK, Babb JS, Moy L, Heller SL. Breast Cancer Screening in High-Risk Men: A 12-year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes. Radiology. 293(2):282-291, 2019 11.
13.	Gao Y, Heller SL, Moy L. Male Breast Cancer in the Age of Genetic Testing: An Opportunity for Early Detection, Tailored Therapy, and Surveillance. Radiographics 2018;38:1289-311.
14.	Medscape. Breast Cancer in Men Overview of Male Breast Cancer. Treatment and Follow-up. Available at: https://emedicine.medscape.com/article/1954174-overview#a4.
15.	NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
16.	Yadav S, Sangaralingham L, Payne SR, et al. Surveillance mammography after treatment for male breast cancer. Breast Cancer Research & Treatment. 194(3):693-698, 2022 Aug.
17.	Brown A, Lourenco AP, Niell BL, et al. ACR Appropriateness Criteria® Transgender Breast Cancer Screening. J Am Coll Radiol 2021;18:S502-S15.
18.	Niell BL, Jochelson MS, Amir T, et al. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update. J Am Coll Radiol 2024;21:S126-S43.
19.	Gaddam S, Heller SL, Babb JS, Gao Y. Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing. Clinical Breast Cancer. 21(1):e74-e79, 2021 02.
20.	American Society of Clinical Oncology (ASCO). Cancer.Net. Hereditary Breast and Ovarian Cancer. Available at: https://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer.
21.	American Cancer Society. About Breast Cancer in Men. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8584.00.pdf.
22.	National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics; Committee on Measuring Sex, Gender Identity, and Sexual Orientation. Measuring Sex, Gender Identity, and Sexual Orientation. In: Becker T, Chin M, Bates N, eds. Measuring Sex, Gender Identity, and Sexual Orientation. Washington (DC): National Academies Press (US) Copyright 2022 by the National Academy of Sciences. All rights reserved.; 2022.
23.	American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.